teduglutide brand names gattex us revestive europe polypeptide glucagonlike analog used treatment short bowel syndrome works promoting mucosal growth possibly restoring gastric emptying europe granted orphan drug status marketed brand revestive nycomed approved united states name gattex december given status orphan drug certain point gut adapt partial resections result short bowel syndrome still parenteral substitution water minerals vitamins depending part gut removed often necessary teduglutide may reduce shorten necessity infusions improving intestinal mucosa possibly common adverse effects clinical studies included abdominal discomfort patients respiratory infections nausea vomiting local reactions injection site headache teduglutide differs natural single amino acid alanine replaced glycine blocks breaking molecule dipeptidyl peptidase increases halflife seven minutes two hours retaining biological actions include maintenance intestinal mucosa increasing intestinal blood flow reducing gastrointestinal motility secretion gastric httpsenwikipediaorgwikiteduglutide